Journal ArticleDOI
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja,Deepu Madduri,Saad Z. Usmani,Andrzej Jakubowiak,Mounzer Agha,Adam D. Cohen,A. Keith Stewart,Parameswaran Hari,Myo Htut,Alexander M. Lesokhin,Abhinav Deol,Nikhil C. Munshi,Elizabeth O'Donnell,David Avigan,Indrajeet Singh,Enrique Zudaire,Tzu-Min Yeh,Alicia J. Allred,Yunsi Olyslager,Arnob Banerjee,Carolyn C. Jackson,Jenna D. Goldberg,Jordan M. Schecter,William Deraedt,Sen Hong Zhuang,Jeffrey R. Infante,Dong Geng,Xiaoling Wu,Marlene J Carrasco-Alfonso,Muhammad Akram,Farah Hossain,Syed Rizvi,Frank Fan,Yi Lin,Thomas Martin,Sundar Jagannath +35 more
TLDR
The CARITUDE-1 trial as discussed by the authors evaluated the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies.About:
This article is published in The Lancet.The article was published on 2021-07-24. It has received 494 citations till now. The article focuses on the topics: Cytokine release syndrome & Progression-free survival.read more
Citations
More filters
Journal ArticleDOI
Teclistamab in Relapsed or Refractory Multiple Myeloma
TL;DR: Teclistamab as mentioned in this paper is a bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on a surface of myeloma cells.
Journal ArticleDOI
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
John F. Thompson,Bryan J. Schneider,Julie R. Brahmer,Amaka Achufusi,Philippe Armand,Meghan Berkenstock,Shailender Bhatia,Lihua E. Budde,Saurin Chokshi,Marianne Davies,Amro Elshoury,Yaron Gesthalter,Aparna Hegde,Michael D. Jain,Benjamin H. Kaffenberger,Melissa G. Lechner,Tian-ren Li,Alissa S. Marr,Suzanne McGettigan,J. P. Mcpherson,Theresa Medina,Nisha Mohindra,Anthony J. Olszanski,Olalekan O. Oluwole,Sandip Pravin Patel,Pradnya D. Patil,Sunil Reddy,Mabel Ryder,Bianca Santomasso,Scott Shofer,Jeffrey A. Sosman,Yinghong Wang,Vlad G. Zaha,Megan V. H. Lyons,Mary A. Dwyer,Lisa E Hang +35 more
TL;DR: The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence.
Journal ArticleDOI
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
TL;DR: Multiple myeloma accounts for approximately 10% of hematologic malignancies in the United States and is the second most common cancer in women.
Journal ArticleDOI
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
TL;DR: The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field as mentioned in this paper .
Journal ArticleDOI
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
TL;DR: CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months as discussed by the authors .
References
More filters
Journal ArticleDOI
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Journal ArticleDOI
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster,Michael R. Bishop,Constantine S. Tam,Edmund K. Waller,Peter Borchmann,Joseph P. McGuirk,Ulrich Jäger,Samantha Jaglowski,Charalambos Andreadis,Jason R. Westin,Isabelle Fleury,Veronika Bachanova,S. Ronan Foley,P. Joy Ho,Stephan Mielke,Stephan Mielke,John M. Magenau,Harald Holte,Serafino Pantano,Lida Bubuteishvili Pacaud,Rakesh Awasthi,Jufen Chu,Özlem Anak,Gilles Salles,Richard T. Maziarz +24 more
TL;DR: The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study.
Journal ArticleDOI
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee,Rebecca Gardner,David L. Porter,Chrystal U. Louis,Nabil Ahmed,Michael C. Jensen,Stephan A. Grupp,Stephan A. Grupp,Crystal L. Mackall +8 more
TL;DR: A novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of C RS based on severity is presented, to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of the syndrome.
Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Related Papers (5)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi,Larry D Anderson,Nina Shah,Deepu Madduri,Jesus G. Berdeja,Sagar Lonial,Noopur Raje,Yi Lin,David S. Siegel,A. Oriol,Philippe Moreau,Ibrahim Yakoub-Agha,Michel Delforge,Michele Cavo,Hermann Einsele,Hartmut Goldschmidt,Hartmut Goldschmidt,Katja Weisel,Katja Weisel,Alessandro Rambaldi,Alessandro Rambaldi,Donna Reece,Fabio Petrocca,Monica Massaro,Jamie N Connarn,Shari Kaiser,Payal Patel,Liping Huang,Timothy B. Campbell,Kristen Hege,Jesús F. San-Miguel +30 more
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial,Hans C. Lee,Ashraf Badros,Suzanne Trudel,Ajay K. Nooka,Ajai Chari,Al-Ola Abdallah,Natalie S. Callander,Nikoletta Lendvai,Douglas W. Sborov,Attaya Suvannasankha,Katja Weisel,Lionel Karlin,Edward N. Libby,Bertrand Arnulf,Thierry Facon,Cyrille Hulin,K. Martin Kortüm,Paula Rodriguez-Otero,Saad Z. Usmani,Parameswaran Hari,Rachid Baz,Hang Quach,Philippe Moreau,Peter M. Voorhees,Ira Gupta,Axel Hoos,Eric Zhi,January Baron,Trisha Piontek,Eric Lewis,Roxanne C. Jewell,Elisha J. Dettman,Rakesh Popat,Simona Degli Esposti,Joanna Opalinska,Paul G. Richardson,Adam D. Cohen +37 more
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje,Jesus G. Berdeja,Yi Lin,David S. Siegel,Sundar Jagannath,Deepu Madduri,Michaela Liedtke,Jacalyn Rosenblatt,Marcela V. Maus,Ashley Turka,Lyh Ping Lam,Richard A. Morgan,Kevin G. Friedman,Monica Massaro,Julie Wang,Greg Russotti,Zhihong Yang,Timothy B. Campbell,Kristen Hege,Fabio Petrocca,M. Travis Quigley,Nikhil C. Munshi,James N. Kochenderfer +22 more
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster,Michael R. Bishop,Constantine S. Tam,Edmund K. Waller,Peter Borchmann,Joseph P. McGuirk,Ulrich Jäger,Samantha Jaglowski,Charalambos Andreadis,Jason R. Westin,Isabelle Fleury,Veronika Bachanova,S. Ronan Foley,P. Joy Ho,Stephan Mielke,Stephan Mielke,John M. Magenau,Harald Holte,Serafino Pantano,Lida Bubuteishvili Pacaud,Rakesh Awasthi,Jufen Chu,Özlem Anak,Gilles Salles,Richard T. Maziarz +24 more